DE69910580D1 - Von der telomerase abgeleitete antigene peptide - Google Patents

Von der telomerase abgeleitete antigene peptide

Info

Publication number
DE69910580D1
DE69910580D1 DE69910580T DE69910580T DE69910580D1 DE 69910580 D1 DE69910580 D1 DE 69910580D1 DE 69910580 T DE69910580 T DE 69910580T DE 69910580 T DE69910580 T DE 69910580T DE 69910580 D1 DE69910580 D1 DE 69910580D1
Authority
DE
Germany
Prior art keywords
telomerase
peptides derived
antigenic peptides
antigenic
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69910580T
Other languages
English (en)
Other versions
DE69910580T3 (de
DE69910580T2 (de
Inventor
Gustav Gaudernack
Amund Eriksen
Mona Moller
Marianne Klemp Gjertsen
Ingvil Saeterdal
Stein Saeboe-Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gemvax AS
Original Assignee
Gemvax AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69910580(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gemvax AS filed Critical Gemvax AS
Publication of DE69910580D1 publication Critical patent/DE69910580D1/de
Application granted granted Critical
Publication of DE69910580T2 publication Critical patent/DE69910580T2/de
Publication of DE69910580T3 publication Critical patent/DE69910580T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE1999610580 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide Expired - Lifetime DE69910580T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO983141 1998-07-08
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt
PCT/NO1999/000220 WO2000002581A1 (en) 1998-07-08 1999-06-30 Antigenic peptides derived from telomerase

Publications (3)

Publication Number Publication Date
DE69910580D1 true DE69910580D1 (de) 2003-09-25
DE69910580T2 DE69910580T2 (de) 2004-06-24
DE69910580T3 DE69910580T3 (de) 2009-11-26

Family

ID=19902234

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69942072T Expired - Lifetime DE69942072D1 (de) 1998-07-08 1999-06-30 Von der Telomerase abgeleitete antigene Peptide
DE1999610580 Expired - Lifetime DE69910580T3 (de) 1998-07-08 1999-06-30 Von der telomerase abgeleitete antigene peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69942072T Expired - Lifetime DE69942072D1 (de) 1998-07-08 1999-06-30 Von der Telomerase abgeleitete antigene Peptide

Country Status (20)

Country Link
US (2) US7030211B1 (de)
EP (4) EP1362597B2 (de)
JP (2) JP4618657B2 (de)
CN (1) CN100376290C (de)
AR (2) AR020601A1 (de)
AT (2) ATE458494T1 (de)
AU (1) AU756094B2 (de)
CA (2) CA2336743C (de)
CY (1) CY1109978T1 (de)
CZ (1) CZ303215B6 (de)
DE (2) DE69942072D1 (de)
DK (2) DK1362597T3 (de)
ES (2) ES2200526T5 (de)
HK (1) HK1039068B (de)
HU (1) HU230007B1 (de)
NO (1) NO313834B1 (de)
PL (1) PL203815B1 (de)
PT (2) PT1093381E (de)
TW (1) TWI261617B (de)
WO (1) WO2000002581A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
GB2321642B8 (en) 1996-10-01 2006-08-22 Geron Corp Human telomerase reverse transcriptase promoter
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
DE69934426T2 (de) 1998-10-29 2007-10-04 Whitehead Institute For Biomedical Research, Cambridge KREBSIMMUNTHERAPIE UND KREBSDIAGNOSE UNTER VERWENDUNG UNIVERSELLER TUMORASSOZIIERTER ANTIGENE EINSCHLIESSLICH hTERT
JP2002541811A (ja) * 1999-04-09 2002-12-10 バイオミラ，インコーポレイテッド テロメラーゼ特異的癌ワクチン
EP1257284A4 (de) * 2000-02-15 2005-12-21 Univ California Ein universelles vakzin und ein verfahren zur behandlung von krebs mit telomerase reverse transkriptase
AU2001241533A1 (en) 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
ES2527946T3 (es) * 2003-03-05 2015-02-02 Dendreon Corporation Composiciones y métodos que emplean polipéptidos de marco de lectura alternativa para el tratamiento de cáncer y enfermedades infecciosas
EP1748067A1 (de) * 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
CA2652310A1 (en) * 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (de) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
JP5207354B2 (ja) * 2008-03-12 2013-06-12 独立行政法人産業技術総合研究所 転写抑制ペプチド及びその遺伝子
EP2310044B1 (de) * 2008-06-16 2016-08-24 Mediolanum Farmaceutici S.p.A. Antitumorale immuntherapie
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
ES2730927T3 (es) 2009-11-10 2019-11-13 Allegro Pharmaceuticals Llc Composiciones y métodos para inhibir la adhesión celular o dirigir agentes diagnósticos o terapéuticos a sitios de unión a RGD
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
EP3581649A1 (de) * 2010-02-16 2019-12-18 Ultimovacs ASA Polypeptide
FR2960542B1 (fr) * 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
JP6106159B2 (ja) 2011-05-09 2017-03-29 アレグロ ファーマシューティカルズ インコーポレイテッドＡｌｌｅｇｒｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｒ−ｇ−システイン酸ペプチドを含む医薬組成物
WO2013167298A1 (en) * 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
EP3333180B1 (de) * 2012-05-11 2019-08-21 KAEL-GemVax Co.,Ltd Antientzündliche peptide und zusammensetzungen die diese enthaltend
US9907837B2 (en) 2012-05-11 2018-03-06 Gemvax & Kael Co., Ltd. Composition for preventing or treating cachexia
JP6272853B2 (ja) * 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
CN104768967B (zh) * 2012-09-19 2019-02-15 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
EP4230644A3 (de) * 2012-09-19 2024-04-24 Gemvax & Kael Co., Ltd. Zellpenetrierendes peptid, konjugat damit und zusammensetzung mit konjugat
EP3611184A1 (de) * 2012-09-19 2020-02-19 Gemvax & Kael Co., Ltd. Zellpenetrierendes peptid, konjugat damit und zusammensetzung mit dem konjugat
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) * 2012-10-22 2014-04-09 南京工业大学 一种制备端粒酶多肽疫苗的方法
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
US9907838B2 (en) * 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
WO2014178680A1 (ko) * 2013-05-03 2014-11-06 주식회사 카엘젬백스 Hsp 발현 억제 펩티드 및 이를 포함하는 조성물
ES2927473T3 (es) 2013-06-07 2022-11-07 Gemvax & Kael Co Ltd GV1001, gemcitabina y capecitabina para su uso en el tratamiento del cáncer de páncreas en pacientes con un nivel inicial de eotaxina elevado
KR102166545B1 (ko) * 2013-06-21 2020-10-16 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
EP3020724A4 (de) * 2013-07-12 2017-01-18 Gemvax & Kael Co., Ltd. Zellenpenetrierendes peptid und konjugat damit
WO2015023132A1 (ko) * 2013-08-14 2015-02-19 주식회사 카엘젬백스 다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CN110755599A (zh) * 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
CN105848667B (zh) 2013-11-22 2020-05-19 珍白斯凯尔有限公司 具有血管生成抑制活性的肽和包含所述肽的组合物
KR102106757B1 (ko) * 2013-11-29 2020-05-06 주식회사 젬백스앤카엘 난소 동결 보존용 펩티드 및 이를 포함하는 조성물
KR20240073156A (ko) * 2013-12-10 2024-05-24 주식회사 젬백스앤카엘 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
KR102314231B1 (ko) * 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
ES2908096T3 (es) 2014-04-11 2022-04-27 Gemvax & Kael Co Ltd Péptido con actividad inhibidora de la fibrosis y composición que lo contiene
KR102232320B1 (ko) 2014-04-30 2021-03-26 주식회사 젬백스앤카엘 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
CN105597078B (zh) * 2014-05-29 2019-01-25 深圳市盛景基因医疗有限公司 一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
KR102397510B1 (ko) * 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
KR102413243B1 (ko) * 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
CN107847551B (zh) * 2015-07-02 2022-02-08 珍白斯凯尔有限公司 具有抗病毒作用的肽和包含其的组合物
KR20170054310A (ko) * 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物
EP3523332B1 (de) 2017-01-06 2021-12-29 Eutilex Co., Ltd. Anti-human-4-1-bb-antikörper und deren verwendung
EP3576764A4 (de) 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. Kras-peptid-impfstoffzusammensetzungen und verfahren zur verwendung
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
JP2023521895A (ja) * 2020-04-17 2023-05-25 リネージ セル セラピューティクス インコーポレイテッド テロメラーゼ逆転写酵素に特異的なｍｈｃ拘束性免疫原性ペプチド、その複合体コンジュゲート、およびそれらを使用する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
WO1995034638A1 (en) 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
ES2184990T3 (es) * 1996-02-12 2003-04-16 Ml Lab Plc Nuevos metodos de vacunacion y vacunas para los mismos que comprenden un acido nucleico que codifica un primer epitope y un peptido que contiene un segundo epitope.
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
WO1998001493A1 (en) * 1996-07-08 1998-01-15 Jvs-Polymers Oy High impact strength biodegradable material
GB2321642B8 (en) * 1996-10-01 2006-08-22 Geron Corp Human telomerase reverse transcriptase promoter
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen

Also Published As

Publication number Publication date
CN100376290C (zh) 2008-03-26
JP5491315B2 (ja) 2014-05-14
EP1093381B2 (de) 2009-07-22
JP2002520293A (ja) 2002-07-09
EP1093381B1 (de) 2003-08-20
JP4618657B2 (ja) 2011-01-26
AR020601A1 (es) 2002-05-22
PT1362597E (pt) 2010-04-14
PT1093381E (pt) 2004-01-30
CA2336743C (en) 2011-10-11
HK1039068B (zh) 2009-02-06
ATE247484T1 (de) 2003-09-15
NO313834B1 (no) 2002-12-09
CZ303215B6 (cs) 2012-05-30
ES2341170T5 (es) 2014-09-09
HK1039068A1 (en) 2002-04-12
EP2316476A2 (de) 2011-05-04
WO2000002581A1 (en) 2000-01-20
PL203815B1 (pl) 2009-11-30
CN1313773A (zh) 2001-09-19
CA2336743A1 (en) 2000-01-20
DK1093381T3 (da) 2003-09-08
AU4534099A (en) 2000-02-01
US7794723B2 (en) 2010-09-14
PL345541A1 (en) 2001-12-17
EP2316476A3 (de) 2011-09-14
CA2748996A1 (en) 2000-01-20
ES2341170T3 (es) 2010-06-16
JP2010252810A (ja) 2010-11-11
ES2200526T3 (es) 2004-03-01
EP2258383B1 (de) 2016-03-09
TWI261617B (en) 2006-09-11
AR077576A2 (es) 2011-09-07
EP1362597B1 (de) 2010-02-24
NO983141L (no) 2000-01-10
DK1093381T4 (da) 2009-09-21
DE69942072D1 (de) 2010-04-08
HUP0104889A2 (hu) 2002-04-29
HU230007B1 (en) 2015-04-28
DE69910580T3 (de) 2009-11-26
DE69910580T2 (de) 2004-06-24
EP1362597A1 (de) 2003-11-19
HUP0104889A3 (en) 2004-04-28
ES2200526T5 (es) 2009-12-11
EP1093381A1 (de) 2001-04-25
CZ200137A3 (en) 2001-06-13
US20060106196A1 (en) 2006-05-18
EP1362597B2 (de) 2014-06-25
EP2258383A2 (de) 2010-12-08
CY1109978T1 (el) 2014-09-10
US7030211B1 (en) 2006-04-18
ATE458494T1 (de) 2010-03-15
AU756094B2 (en) 2003-01-02
EP2316476B1 (de) 2015-11-25
EP2258383A3 (de) 2011-05-11
DK1362597T3 (da) 2010-06-14

Similar Documents

Publication Publication Date Title
DE69910580D1 (de) Von der telomerase abgeleitete antigene peptide
DK1042359T3 (da) k-Opioidreceptorpeptider
NO982097L (no) Peptider
NO982098D0 (no) Peptider
ATE317854T1 (de) Hepatitis c inhibitor peptide
ATE259241T1 (de) Wässrige peptidzubereitung
NO985680D0 (no) Peptidderivater
ZA9811316B (en) Novel hepatitis C virus NS5B protein
TR199501255A2 (tr) Immunomodülatör tesirli yeni peptidler.
ATE403722T1 (de) Chimäres pflanzenvirus mit peptiden von mucin
DE69933647D1 (de) Rekombinante lysophosphatidsäure - phosphatase.
FI970168A (fi) Peptidejä
DE69931010D1 (de) Peptide mit osteogener Aktivität
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
FI974044A (fi) Liesi
EP1113777A4 (de) Neues hepatitis c viruspeptid und seine verwendung
GB0030309D0 (en) Antibodies,Peptides,Analogs and uses thereof
FI970744A0 (fi) Uusia immuuniehkäiseviä peptidejä
FI973371A0 (fi) Nya isolerade peptider
NO20013933D0 (no) Peptider
NO996412D0 (no) Antigene peptider
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
ITGE960040A0 (it) Pentapeptide.
SE9802536D0 (sv) Novel peptides

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings